Italian study reveals Real-World impact of targeted leukemia drug

NCT ID NCT03898128

Completed Knowledge-focused Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at the medical records of 84 people with acute lymphoblastic leukemia (ALL) who received a drug called anti-CD22 outside of clinical trials. The goal was to see how safe and effective the treatment was in everyday hospital use. Researchers collected information on side effects, survival, and how long patients stayed cancer-free to better understand the drug's real-world benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

AUSL Romagna

Ravenna, RA, 48121, Italy
Azienda ULSS2 Marca Trevigiana

Treviso, TV, 31100, Italy
Irst Irccs

Meldola (FC), FC, 47014, Italy
Ospedale S. Eugenio

Roma, 00144, Italy
ULSS 3 Serenissima

Mestre, Venezia, 30174, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.